Creative Planning cut its holdings in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 7.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 189,367 shares of the company’s stock after selling 15,815 shares during the period. Creative Planning owned approximately 0.13% of Lineage Cell Therapeutics worth $169,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of LCTX. Defender Capital LLC. bought a new stake in Lineage Cell Therapeutics during the third quarter worth approximately $3,709,000. State Street Corp bought a new stake in Lineage Cell Therapeutics during the third quarter worth approximately $1,738,000. Rhumbline Advisers bought a new stake in Lineage Cell Therapeutics during the third quarter worth approximately $177,000. California State Teachers Retirement System bought a new stake in Lineage Cell Therapeutics during the third quarter worth approximately $163,000. Finally, Commonwealth Equity Services LLC bought a new stake in Lineage Cell Therapeutics during the third quarter worth approximately $112,000.
LCTX has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Lineage Cell Therapeutics in a report on Monday, February 10th. Zacks Investment Research cut Lineage Cell Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $2.67.
Shares of NYSEAMERICAN:LCTX opened at $1.51 on Friday. Lineage Cell Therapeutics, Inc. has a 12 month low of $0.53 and a 12 month high of $1.73. The business’s 50 day moving average price is $0.98.
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.94 million.
Lineage Cell Therapeutics Company Profile
Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
Further Reading: Balance Sheet
Want to see what other hedge funds are holding LCTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX).
Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.